Hanxin Lu
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Hanxin Lu's research focuses on the development and evaluation of novel therapeutic and preventive strategies, particularly in the areas of cardiovascular disease and immunology. Lu has investigated VXX-401, an investigational PCSK9 vaccine aimed at reducing low-density lipoprotein cholesterol (LDL-C) in non-human primates. Further research includes the preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide, another approach for managing cardiovascular risk factors.
Beyond cardiovascular health, Lu's work has also explored broader public health and disease mechanisms. This includes studies on the impact of social determinants, lifestyle, and environmental factors like air pollution on allergic diseases and their comorbidities, using multi-state analysis of prospective cohort data. Additionally, Lu has examined health information-seeking behaviors among specific demographic groups, such as Baby Boomers in Taiwan.
Lu's scholarship metrics indicate a significant body of work, with an h-index of 20, 29 total publications, and over 1,500 citations. Lu collaborates with other faculty members at the University of Central Arkansas, including Alexander Chen, Michael J. Rubach, and Mark E. McMurtrey, and leads a research group.
Metrics
- h-index: 20
- Publications: 29
- Citations: 1,581
Selected Publications
-
Impact of social determinants, lifestyle and air pollution on the allergic diseases and comorbidities: A multi-state analysis of a prospective cohort (2025)
-
Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan (2025)
-
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide (2025)
-
A Study of Aesthetic Characteristics and Expressions of Photographic Art (2024)
-
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys (2024)
-
VXX-401, AN INVESTIGATIONAL PCSK9 VACCINE FOR THE PREVENTION OF CARDIOVASCULAR DISEASE (2023)
-
Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge (2019)
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection (2019)
-
Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein (2019)
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge (2018)
-
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age (2017)
-
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults (2017)
-
Strategies for enhancing success in digital tablet use by older adults: A pilot study (2016)
-
Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice (2016)
-
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age (2015)
Collaboration Network
Top Collaborators
- Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan
- Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan
- Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan
- Preventive Health Care Information Seeking Behaviors among Baby Boomers in Taiwan
Similar Researchers
Based on overlapping research topics